Jazz Pharmaceuticals plc – Stock Rating Reaffirmed by FBR Capital Markets (JAZZ)
Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) traded up 6.97% during mid-day trading on Wednesday, hitting $162.02. The stock had a trading volume of 1,982,938 shares. Jazz Pharmaceuticals plc – has a 52-week low of $69.35 and a 52-week high of $176.60. The stock has a 50-day moving average of $141.9 and a 200-day moving average of $142.6. The company has a market cap of $9.623 billion and a price-to-earnings ratio of 115.18.
Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) last released its earnings data on Thursday, May 8th. The company reported $1.61 EPS for the quarter, missing the Thomson Reuters consensus estimate of $1.79 by $0.18. The company had revenue of $247.00 million for the quarter, compared to the consensus estimate of $254.86 million. During the same quarter in the prior year, the company posted $1.37 earnings per share. The company’s quarterly revenue was up 25.8% on a year-over-year basis. Analysts expect that Jazz Pharmaceuticals plc – will post $8.07 EPS for the current fiscal year.
Other equities research analysts have also recently issued reports about the stock. Analysts at Zacks reiterated a “neutral” rating on shares of Jazz Pharmaceuticals plc – in a research note on Friday, June 20th. They now have a $157.00 price target on the stock. Separately, analysts at JMP Securities initiated coverage on shares of Jazz Pharmaceuticals plc – in a research note on Tuesday, June 17th. They set an “outperform” rating and a $179.00 price target on the stock. Finally, analysts at Wells Fargo & Co. initiated coverage on shares of Jazz Pharmaceuticals plc – in a research note on Tuesday, June 10th. They set an “outperform” rating on the stock. Five analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. Jazz Pharmaceuticals plc – has an average rating of “Buy” and a consensus target price of $168.60.
In other Jazz Pharmaceuticals plc – news, Director Seamus Mulligan unloaded 50,000 shares of the stock in a transaction dated Wednesday, June 25th. The stock was sold at an average price of $149.69, for a total transaction of $7,484,500.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.